A. T. M. Tanveer Hasan
Research Subjects
A. T. M. Tanveer Hasan has a total of 94 co-authors. Here are the top co-authors by number of shared publications:
- Syahrul Sazliyana Shaharir
Department of Medicine, Faculty of Medicine, Universiti Kebangsaan Malaysia, Cheras 56000, Malaysia
4 shared publications - Abraham Edgar Gracia-Ramos
Department of Internal Medicine, General Hospital, National Medical Center La Raza, Instituto Mexicano del Seguro Social , Mexico City
3 shared publications - Ai Lyn Tan
Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK; NIHR Leeds Biomedical Research Centre, Chapel Allerton Hospital, Leeds, UK
3 shared publications - Ashima Makol
Division of Rheumatology, Mayo Clinic, Rochester, USA
3 shared publications - Babur Salim
Rheumatology Department Fauji Foundation Hospital Rawalpindi Pakistan
3 shared publications - Binit Vaidya
National Center for Rheumatic Diseases Kathmandu Nepal
3 shared publications
Latest Publications
- Open Access
- 20 October 2025
- Published by Ordient Publishers in Pacific Journal of Medical Research
- Vol. 2 (4) , 322-329
Factors Associated with Remission of Lupus Nephritis: A Case–Control Study from a Tertiary Care Center, Bangladesh
Background: Lupus nephritis (LN) contributes significantly to morbidity and mortality in systemic lupus erythematosus and may cause permanent renal damage when left untreated or undertreated. Although modern treatment with immunomodulatory drugs has improved prognosis, enormous variability exists between patients, and few predictors are available to ensure that remission is achieved, especially within developing countries. Methods: This case–control study was conducted at the Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, from September 2020 to March 2021. Adults (≥18 years) with lupus nephritis who received at least one year of treatment were included. Patients achieving remission were classified as cases, and those without remission as controls. Sociodemographic, clinical, laboratory, histopathological, and treatment-related variables were evaluated. Comparisons between groups were performed using the Chi-square or Fisher’s exact test where applicable. Multivariate logistic regression analysis was used to determine independent predictors of remission, considering p < 0.05 as statistically significant. Results: The cohort was characterized by a young mean age and marked female predominance, with proliferative lupus nephritis comprising most cases. Musculoskeletal involvement, serositis, and neurological manifestations were significantly more frequent among non-remitters. Patients who failed to achieve remission had significantly higher inflammatory and immunological activity, including higher ESR, proteinuria, anti-dsDNA titers, lower complement levels, and higher SELENA–SLEDAI scores. On multivariate analysis, class III lupus nephritis, lower baseline proteinuria, preserved renal function, and low chronicity index were independently associated with remission. A ≥50% reduction in proteinuria at 3 months emerged as the strongest predictor of remission, whereas induction regimen type was not independently associated with outcome. Conclusion: Remission of lupus nephritis is primarily determined by baseline renal pathology and early immunological response to treatment rather than the choice of induction therapy alone.
- 20 October 2025
- Published by Ordient Publishers in Pacific Journal of Medical Research
- Vol. 2 (4) , 322-329
Open AccessFactors Associated with Remission of Lupus Nephritis: A Case–Control Study from a Tertiary Care Center, Bangladesh
Background: Lupus nephritis (LN) contributes significantly to morbidity and mortality in systemic lupus erythematosus and may cause permanent renal damage when left untreated or undertreated. Although modern treatment with immunomodulatory drugs has improved prognosis, enormous variability exists between patients, and few predictors are available to ensure that remission is achieved, especially within developing countries. Methods: This case–control study was conducted at the Department of Rheumatology, Bangabandhu Sheikh Mujib Medical University (BSMMU), Dhaka, from September 2020 to March 2021. Adults (≥18 years) with lupus nephritis who received at least one year of treatment were included. Patients achieving remission were classified as cases, and those without remission as controls. Sociodemographic, clinical, laboratory, histopathological, and treatment-related variables were evaluated. Comparisons between groups were performed using the Chi-square or Fisher’s exact test where applicable. Multivariate logistic regression analysis was used to determine independent predictors of remission, considering p < 0.05 as statistically significant. Results: The cohort was characterized by a young mean age and marked female predominance, with proliferative lupus nephritis comprising most cases. Musculoskeletal involvement, serositis, and neurological manifestations were significantly more frequent among non-remitters. Patients who failed to achieve remission had significantly higher inflammatory and immunological activity, including higher ESR, proteinuria, anti-dsDNA titers, lower complement levels, and higher SELENA–SLEDAI scores. On multivariate analysis, class III lupus nephritis, lower baseline proteinuria, preserved renal function, and low chronicity index were independently associated with remission. A ≥50% reduction in proteinuria at 3 months emerged as the strongest predictor of remission, whereas induction regimen type was not independently associated with outcome. Conclusion: Remission of lupus nephritis is primarily determined by baseline renal pathology and early immunological response to treatment rather than the choice of induction therapy alone.
- Open Access
- 25 September 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (4) , 2133-2142
The impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset
The presence of comorbidities can substantially affect patients’ quality of life, but data regarding their impact on idiopathic inflammatory myopathies (IIMs) are limited. We examined the prevalence of comorbidities in IIM patients, other autoimmune rheumatic diseases (oAIRDs), and healthy controls (HCs), using data from the self-reported COVAD-2 survey. We defined Basic Multimorbidity (BM) as the presence of ≥ 2 non-rheumatic chronic conditions and Complex Multimorbidity (CM) as the presence of ≥ 3 non-rheumatic chronic conditions affecting ≥3 organ systems. Hierarchical Clustering on Principal Components was performed for grouping. Among the COVAD respondents, 1558 IIMs, 4591 oAIRDs, and 3652 HCs were analysed. IIMs exhibited a high burden of comorbidities (OR: 1.62 vs oAIRDs and 2.95 vs HCs, p< 0.01), BM (OR 1.66 vs oAIRDs and 3.52 vs HCs, p< 0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs, p< 0.01), and mental health disorders (MHDs) (OR 1.33 vs oAIRDs and 2.63 vs HCs, p< 0.01). Among the IIM patients, those with comorbidities or MHDs had lower PROMIS Global Physical (PGP), PROMIS Global Mental (PGM), and PROMIS Physical Function (SF10) scores, and higher fatigue (F4a) scores (all p< 0.001). PGP, PGM, SF10a and F4a were influenced by age, active disease, BM, and MHDs. Four distinct clusters were identified among the IIMs according to comorbidities and PROMIS scores. Patients with IIMs have a higher burden of comorbidities that influence physical and mental health, identifiable as clinical clusters for optimized and holistic management approaches.
- 25 September 2024
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 64 (4) , 2133-2142
Open AccessThe impact of multimorbidity on Quality of Life in inflammatory myopathies: A cluster analysis from the COVAD dataset
The presence of comorbidities can substantially affect patients’ quality of life, but data regarding their impact on idiopathic inflammatory myopathies (IIMs) are limited. We examined the prevalence of comorbidities in IIM patients, other autoimmune rheumatic diseases (oAIRDs), and healthy controls (HCs), using data from the self-reported COVAD-2 survey. We defined Basic Multimorbidity (BM) as the presence of ≥ 2 non-rheumatic chronic conditions and Complex Multimorbidity (CM) as the presence of ≥ 3 non-rheumatic chronic conditions affecting ≥3 organ systems. Hierarchical Clustering on Principal Components was performed for grouping. Among the COVAD respondents, 1558 IIMs, 4591 oAIRDs, and 3652 HCs were analysed. IIMs exhibited a high burden of comorbidities (OR: 1.62 vs oAIRDs and 2.95 vs HCs, p< 0.01), BM (OR 1.66 vs oAIRDs and 3.52 vs HCs, p< 0.01), CM (OR: 1.69 vs AIRDs and 6.23 vs HCs, p< 0.01), and mental health disorders (MHDs) (OR 1.33 vs oAIRDs and 2.63 vs HCs, p< 0.01). Among the IIM patients, those with comorbidities or MHDs had lower PROMIS Global Physical (PGP), PROMIS Global Mental (PGM), and PROMIS Physical Function (SF10) scores, and higher fatigue (F4a) scores (all p< 0.001). PGP, PGM, SF10a and F4a were influenced by age, active disease, BM, and MHDs. Four distinct clusters were identified among the IIMs according to comorbidities and PROMIS scores. Patients with IIMs have a higher burden of comorbidities that influence physical and mental health, identifiable as clinical clusters for optimized and holistic management approaches.
- 15 November 2023
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (1)
Flares of autoimmune rheumatic disease following COVID‐19 infection: Observations from the COVAD study
- 15 November 2023
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 27 (1)
Flares of autoimmune rheumatic disease following COVID‐19 infection: Observations from the COVAD study
- Open Access
- 23 June 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (9) , 1651-1664
Long-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study
Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb–June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35–58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2–7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.
- 23 June 2023
- Published by Springer Nature in Rheumatology International
- Vol. 43 (9) , 1651-1664
Open AccessLong-term safety of COVID vaccination in individuals with idiopathic inflammatory myopathies: results from the COVAD study
Limited evidence on long-term COVID-19 vaccine safety in patients with idiopathic inflammatory myopathies (IIMs) continues to contribute to vaccine hesitancy. We studied delayed-onset vaccine adverse events (AEs) in patients with IIMs, other systemic autoimmune and inflammatory disorders (SAIDs), and healthy controls (HCs), using data from the second COVID-19 Vaccination in Autoimmune Diseases (COVAD) study. A validated self-reporting e-survey was circulated by the COVAD study group (157 collaborators, 106 countries) from Feb–June 2022. We collected data on demographics, comorbidities, IIM/SAID details, COVID-19 history, and vaccination details. Delayed-onset (> 7 day) AEs were analyzed using regression models. A total of 15165 respondents undertook the survey, of whom 8759 responses from vaccinated individuals [median age 46 (35–58) years, 74.4% females, 45.4% Caucasians] were analyzed. Of these, 1390 (15.9%) had IIMs, 50.6% other SAIDs, and 33.5% HCs. Among IIMs, 16.3% and 10.2% patients reported minor and major AEs, respectively, and 0.72% (n = 10) required hospitalization. Notably patients with IIMs experienced fewer minor AEs than other SAIDs, though rashes were expectedly more than HCs [OR 4.0; 95% CI 2.2–7.0, p < 0.001]. IIM patients with active disease, overlap myositis, autoimmune comorbidities, and ChadOx1 nCOV-19 (Oxford/AstraZeneca) recipients reported AEs more often, while those with inclusion body myositis, and BNT162b2 (Pfizer) recipients reported fewer AEs. Vaccination is reassuringly safe in individuals with IIMs, with AEs, hospitalizations comparable to SAIDs, and largely limited to those with autoimmune multimorbidity and active disease. These observations may inform guidelines to identify high-risk patients warranting close monitoring in the post-vaccination period.
- Open Access
- 4 May 2021
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (6) , 733-745
Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID‐19 pandemic
Aim: To update previous guidance of the Asia Pacific League of Associations for Rheumatology (APLAR) on the management of patients with rheumatic and musculoskeletal diseases (RMD) during the coronavirus disease 2019 (COVID‐19) pandemic.Methods: Research questions were formulated focusing on diagnosis and treatment of adult patients with RMD within the context of the pandemic, including the management of RMD in patients who developed COVID‐19. MEDLINE was searched for eligible studies to address the questions, and the APLAR COVID‐19 task force convened 2 meetings through video conferencing to discuss its findings and integrate best available evidence with expert opinion. Consensus statements were finalized using the modified Delphi process.Results: Agreement was obtained around key aspects of screening for or diagnosis of COVID‐19; management of patients with RMD without confirmed COVID‐19; and management of patients with RMD with confirmed COVID‐19. The task force achieved consensus on 25 statements covering the potential risk of acquiring COVID‐19 in RMD patients, advice on RMD medication adjustment and continuation, the roles of telemedicine and vaccination, and the impact of the pandemic on quality of life and on treatment adherence.Conclusions: Available evidence primarily from descriptive research supported new recommendations for aspects of RMD care not covered in the previous document, particularly with regard to risk factors for complicated COVID‐19 in RMD patients, modifications to RMD treatment regimens in the context of the pandemic, and COVID‐19 vaccination in patients with RMD.
- 4 May 2021
- Published by Wiley in International Journal of Rheumatic Diseases
- Vol. 24 (6) , 733-745
Open AccessUpdated APLAR consensus statements on care for patients with rheumatic diseases during the COVID‐19 pandemic
Aim: To update previous guidance of the Asia Pacific League of Associations for Rheumatology (APLAR) on the management of patients with rheumatic and musculoskeletal diseases (RMD) during the coronavirus disease 2019 (COVID‐19) pandemic.Methods: Research questions were formulated focusing on diagnosis and treatment of adult patients with RMD within the context of the pandemic, including the management of RMD in patients who developed COVID‐19. MEDLINE was searched for eligible studies to address the questions, and the APLAR COVID‐19 task force convened 2 meetings through video conferencing to discuss its findings and integrate best available evidence with expert opinion. Consensus statements were finalized using the modified Delphi process.Results: Agreement was obtained around key aspects of screening for or diagnosis of COVID‐19; management of patients with RMD without confirmed COVID‐19; and management of patients with RMD with confirmed COVID‐19. The task force achieved consensus on 25 statements covering the potential risk of acquiring COVID‐19 in RMD patients, advice on RMD medication adjustment and continuation, the roles of telemedicine and vaccination, and the impact of the pandemic on quality of life and on treatment adherence.Conclusions: Available evidence primarily from descriptive research supported new recommendations for aspects of RMD care not covered in the previous document, particularly with regard to risk factors for complicated COVID‐19 in RMD patients, modifications to RMD treatment regimens in the context of the pandemic, and COVID‐19 vaccination in patients with RMD.